Ceftriaxone

C difficile risk
High
Oral Bioavailability
N/A

Dosing

  • Meningitis, IE: 2 g q12h

  • Bone/joint: 2 g q24h

  • Mod-Severe UTI, IA, PNA, SSTI >/=100 kg: 2 g q24h

  • Mild UTI, PNA/SSTI < 100 kg: 1 g q24h

Do not exceed 1 g q24h

General Information

Empiric therapy of:

  • Bacterial meningitis

  •  Nosocomial gram negative infections (except Pseudomonas)

  •  Spontaneous bacterial peritonitis

  •  Hospitalized community or nursing home acquired pneumonia in combination with a macrolide

  • Allergy/rash (immediate or delayed)

  • Cytopenias

  • Eosinophilia

  • Hepatic & renal laboratory abnormalities

  • Pseudocholelithiasis. Unclear clinical significance. Uncommonly symptomatic, but should be discontinued in patients developing signs and symptoms of gallbladder disease and/or who have abnormal ultrasound findings

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.